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1. Introduction 
Lung cancer is a common disease with approximately 3-million new cases per year 
worldwide and is the leading cause of cancer-related death in many countries. Eighty 
percent of the lung cancers are non-small cell lung cancers (NSCLC) and 20% are small cell 
lung cancers (SCLC) [1]. The imaging diagnostic assessment of patients with lung cancer 
includes morphological imaging modalities such as chest X-ray, Computed Tomography 
(CT) and Magnetic Resonance (MR) as well as metabolic imaging modalities such as nuclear 
medicine procedures, including Positron Emission Tomography (PET) and PET/CT. Staging 
a patient with lung cancer implies an accurate determination of the size of the tumor, the 
potential infiltration of the tumor into the adjacent structures, the involvement of hilar and 
mediastinal lymph nodes and the detection of distant metastases. Till recently, CT was the 
routine imaging procedure for staging patients with NSCLC. The success of CT is related to 
the very detailed imaging information of the localization and extent of the tumor, the 
presence of enlarged lymph nodes and the presence of metastatic disease [2]. PET has more 
recently been introduced in tumor staging and it has been used successfully for detection of 
primary tumors, metastases, early tumor recurrence, and for the detection of metastatic 
lymph nodes [3, 4]. This imaging modality possesses a greater sensitivity for detection of 
malignancy though it is inhibited by relatively poor spatial resolution and anatomical 
localization of disease. Combining detailed anatomical information obtained by CT with 
metabolic information from PET seems logical, therefore. Integrated PET/CT is the most 
recent approach to post hoc image fusion. It combines these image modalities into one 
scanner that acquires accurately aligned anatomical and metabolical images in the same 
scanning session [1].  
2. Evaluation of a solitary pulmonary nodule 
Lung lesions detected in a chest radiograph, incidentally or by systematic investigation, need a 
definite confirmation of diagnosis. The key point is the evaluation of malignancy in peripheral 
lung nodules. A solitary pulmonary nodule (SPN) is defined as a focal round or oval lung 
lesion with a diameter smaller than 3 cm, completely surrounded by normal lung tissue, not 
associated with atelectasis or adenopathies. Lung lesions greater than 3 cm are classified as 
masses [5]. Non-invasive evaluation of SPN is usually performed by different imaging 
procedures including CT, MR, PET and PET/CT. CT is considered to be an excellent tool for 
the detection and localization of SPNs with a good sensitivity (96%, range 91–98%) but a poor 
specificity (50%, range 41–58%) [6].  CT provides data regarding the nodule shapes, borders 
and density [7]. Central or concentric calcifications, round shape or a morphologic stability 
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over 2 years are features of benignancy. On the contrary, non-demarcated borders, 
calcifications with eccentric appearance or spiculated pattern, a doubling time of <10 month 
and cavitation or pseudocavitation are features of malignancy [8, 9]. Contrast enhanced CT can 
be used to characterize SPN. Enhancement of  the pulmonary nodule with 15 Hounsfield Units 
(HU) has a sensitivity and specificity of 98% and 58% in the detection of malignancy, 
respectively and the absence of lung nodule enhancement is strongly predictive of a benign 
diagnosis (negative predictive value of 96.5%) [10].  
Several studies showed that PET had similar sensitivity (92–95%) but superior specificity 
(72–83%) as compared to CT for the characterization of SPN [11, 12]. In one of the largest 
published studies (450 patients) with lung nodules evaluated with PET, Gould et al. 
reported a high PET sensitivity (94.2%) and specificity (83.3%) [12]. Lower sensitivity 
(91.7%) but similar specificity (82.3%) was observed by Fletcher et al. in a population of 344 
patients [13]. Malignant lesions with a size of more than 10 mm in diameter are detected 
with a sensitivity of 96% [14]. Gupta et al. showed that PET using Fluor-Deoxy-Glucose 
(FDG) as tracer, is highly accurate in differentiating malignant from benign solitary 
pulmonary nodules for sizes from 6 to 30 mm when radiographic findings are indeterminate 
[15]. An important contribution of two more recent meta-analyses [16, 17] is the assessment 
of the performance of FDG-PET in small lung nodules. Nomori et al. demonstrated that the 
sensitivity clearly decreases for malignant lung lesions of less than 10 mm in diameter [18]. 
For technical reasons, the lower limit has to be set in dependence from the spatial resolution 
and will be around 6–10 mm according to the most common PET scanners used. Thus, FDG-
PET is not indicated for the evaluation of solitary pulmonary nodules of less than 6–10 mm. 
The meta-analysis of Ung et al. mentioned that the accuracy for the characterization of lung 
lesions by FDG-PET depends on the amount of tumoral FDG uptake given as Standardized 
Uptake Value (SUV) [16]. Grgic et al. reported that it is possible to estimate the individual 
risk for malignancy considering the SUVmax of a given nodule and clinically relevant 
information [19]. The authors reported that the mean SUVmax of malignant SPNs was 
higher than benign lesions (SUVmax 9.7 ± 5.5 vs. 2.6 ± 2.5; P < 0.01). 
False positive FDG-PET findings are represented by lung inflammatory conditions such as 
pneumonia, pyogenic abscesses, aspergillosis, granulomatous diseases (tuberculosis, 
sarcoidosis, histoplasmosis, Wegener's granulomatosis) [20]. False negative findings on PET 
images can be the result of small lesion size (<1 cm) or tumor types characterized by low 
glucose metabolism (such as Neuro Endocrine Tumors (NET), Broncho Alveolar Cell 
Carcinomas (BAC) or pulmonary carcinoids [21, 22].  
The widespread introduction in clinical practice of FDG PET/CT has allowed a more accurate 
assessment of SNPs. With integrated PET/CT, additional certainty to the presence or absence 
of FDG uptake in the pulmonary nodule can be achieved because morphologic CT criteria and 
metabolical PET criteria are available simultaneously [23]. Kim et al. reported a sensitivity of 
97% and a specificity of 85% for the detection of SPNs, concluding that the combination of the 
anatomical and metabolic images preserves the sensitivity of the CT and the specificity of the 
PET scan, but improves significantly the overall accuracy [24, 25]. 
3. Assessment of T stage 
The most significant improvement in  staging results with combined PET/CT compared with 
PET alone relates to T staging. This superiority is attributed entirely to the CT component of 
the examination [26]. The major benefit of PET/CT lies in the direct link between the 
information on metabolic changes of structures and the highly detailed anatomic CT 
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information of these structures. Recent published studies showed that PET/CT is the best 
noninvasive imaging technique for correct prediction of T-stage: PET/CT correctly predicts the 
T-stage in +/_ 82% of cases, in comparison with 55, 68 and 76% for PET, CT and visual 
correlation of PET and CT, respectively [20]. Halpern et al.[27] demonstrated an accuracy rate 
of 97% with PET/CT compared with 67% with PET only. Another study by Cerfolio et al. [28]  
showed that PET/CT more accurately predicted T status (70% of cases) than did PET alone 
(47%).  Lardinois et al. described accuracy rates for T staging with PET/CT and CT as 88% and 
58%, respectively [29]. Pauls et al. found that the advantages of integrated PET/CT also 
depend on the histological T-stage of the primary tumor [30]. Changes of the therapeutic 
strategy due to PET/CT are especially seen in T3 and T4 tumors. 
It has been demonstrated that integrated PET/CT is a useful tool for the detection of tumor 
invasion into the chest wall [1, 29, 31]. Due to the exact anatomic correlation to the FDG 
uptake, the delineation of the primary tumor can be defined precisely. Integrated PET/CT 
provides important information on mediastinal infiltration as well. In addition, PET can be 
helpful in evaluating the cause of pleural effusions [29] (figure 1). One of the most important 
attributes of PET/CT is the ability to distinguish between tumor and distal atelectasis 
(figure 2). This is particularly important for the planning of radiotherapy in patients with 
lung cancer associated with atelectasis [23]. Table 1 summarizes the most important studies 
concerning T-staging with PET/CT. 
 
 
Fig. 1. A 74-year-old woman with an abdominal tumor. CT showed a pleural effusion in the 
right hemi-thorax (fig 1a). CT could not demonstrate contrast-captated pleural lesions 
suspect for pleural metastases. PET demonstrates FDG-uptake in the dorsal part of the right 
hemi-thorax (fig 1b). Integrated PET/CT localizes this FDG-uptake in the pleura, indicating 
pleural metastases. This was confirmed after pleuroscopy.  
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Fig. 2. A 57-year-old man with a central tumor in the right lung. CT demonstrates a central 
mass with a retro-obstructive consolidation in the right upper lobe (fig 2a). PET demonstrates 
FDG uptake in the right hilar region corresponding with the central tumor (fig 2b). Integrated 
PET/CT demonstrates the central tumor in the right lung and can delineate the tumor from 
the surrounding retro-obstructive consolidation in the right upper lobe (fig 2c). 
 
Author Year Number of Subjects Accuracy (%)
T staging
Lardinois [29] 2003 40 88
Antoch [31] 2003 27 94
Cerfolio [28] 2004 129 70
Shim [41] 2005 106 86
Halpern [27] 2005 36 97
De Wever [1] 2007 50 86
Average 388 87
Table 1. Accuracy of PET/CT in T staging 
4. Assessment of N stage 
The accuracy of CT for the prediction of intrathoracic nodal spread of tumor remains limited 
and the more recently developed CT systems do not change this [7]. Lymph node size 
(diameter >10 mm in short axis)  is used as the only criterion to determine metastatic 
disease. Different studies with CT have shown a marked heterogeneity in the results, going 
from 52% to 69% for sensitivity and from 69% to 82% for specificity [32].  
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Over the past years, several studies have found that FDG-PET has a significantly higher 
sensitivity and specificity than CT in the detection of tumoral involvement of mediastinal 
lymph nodes[33-35]. Meta-analyses have confirmed sensitivities ranging between 79–85% 
and specificities between 89–92% [36-38]. The clinical importance of FDG-PET lies in the 
high negative predictive value in lymph node staging, which has been estimated as >90% in 
several studies [39]. Some studies have demonstrated that the accuracy of PET imaging in 
the mediastinum is dependent on the size of lymph nodes. PET scanning is more sensitive 
but less specific when CT imaging identifies enlarged nodes. A median sensitivity and 
specificity of PET scans of 100 and 78%, respectively, in patients with enlarged lymph nodes 
has been reported [40]. It has been concluded that PET scanning is very accurate in 
identifying malignant lymph nodes when lymph nodes are enlarged. Conversely, PET 
scanning is less sensitive but more specific in patients with normal-sized mediastinal nodes 
on CT. It has been shown that CT of the mediastinum is falsely negative in about 20% of 
patients with normal-sized malignant lymph nodes. Gould et al. reported a median 
sensitivity and specificity in these patients of 82 and 93%, respectively [38]. There is an 
ongoing controversy whether a negative PET scan can be used to obviate further invasive 
mediastinal staging in patients with enlarged lymph nodes on CT. Microscopic foci of 
metastases cannot be detected with any imaging modality. In our institution, in patients 
with negative PET scan but with enlarged mediastinal lymph nodes on CT further 
evaluation by EBUS or mediastinoscopy will be performed.  
PET/CT result in improvement of nodal staging compared with PET alone due to ability to 
reveal the exact location of metastatic lymph nodes [26].  Accurate anatomic correlation is of 
benefit for exact localization of a solitary lymph node metastasis and thus allows exact 
classification as N1 or N2 disease. PET/CT is also important when identifying 
supraclavicular N3 disease [26]. Initial studies demonstrated a pooled average sensitivity, 
specificity, positive predictive value, negative predictive value and accuracy of PET/CT of 
73%, 80%, 78%, 91% and 87%, respectively. Shim and colleagues [41] demonstrated accuracy 
rate for PET/CT and CT in N disease of 84% and 69%, respectively. In a recent study by Kim 
et al.[42]  the overall sensitivity, specificity and accuracy of PET/CT for mediastinal nodal 
staging were 61%, 96% and 86%, respectively Another study by Yi et al. [43] reported that in 
T1 stage NSCLC, contrast-enhanced helical dynamic CT better predicts mediastinal nodal 
metastasis than PET/CT, whereas PET/CT shows perfect specificity and higher accuracy 
than helical dynamic CT [26]. Table 2 summarizes the most important studies concerning N 
stage with PET/CT. The benefit of PET/CT compared with PET for nodal staging appears to 
lie in an increase in specificity and positive predictive value, and the benefit in accuracy of 
PET/CT is due to the appropriate assignment of focally increased FDG uptake. This 
emphasizes the importance of anatomic information in conjunction with PET imaging for 
appropriate PET image interpretation.  
False-negative results can occur when the cancer involvement of the mediastinal nodes is 
low (micro metastases). Because of limitations in spatial resolution of PET, it is often not 
possible to distinguish between a central tumor and hilar lymph nodes or adjacent 
mediastinal lymph nodes. Additionally, differentiation between malignant lymph node and 
residual brown fat or inflammatory lymph nodes can be challenging [44]. Therefore, 
mediastinal staging with mediastinoscopy or endo-bronchial ultrasonography or endo-
eosophageal ultrasonography remains the standard for mediastinal staging, even if not all 
mediastinal lymph nodes can be accessed with each technique alone [45] (figures 3-5). On 
the other hand, previous or concomitant inflammatory and infectious conditions even as 
granulomatous diseases are mainly responsible for false-positive results of PET/CT.  
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Author Year
Number of 
Subjects
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
Accuracy 
(%) 
N Staging
Lardinois [29] 2003 40 81 
Cerfolio [28] 2004 129 77-92 78 
Shim [41] 2005 106 85 84 
Halpern [27] 2005 36 78 
Kim [59] 2006 150 47 100 100 87 88 
De Wever [1] 2007 50 80 
Yi [43] 2007 143 56 100 100 88 90 
Lee 2007 126 86 81 56 95 82 
Melek [60] 2008 170 74 73 55 87 74 
Yang [61] 2008 122 85 
Billé [62] 2009 159 45 94 67 88 85 
Average 1231 82 
PPV: Positive Predictive Value 
NPV: Negative Predictive Value 
Table 2. Accuracy of PET/CT in N staging 
 
 
Fig. 3. A 55-year-old woman with an atypical carcinoid tumor in the right middle lobe. CT 
showed enlarged lymph nodes in the subcarinal (fig 3a) and right paratracheal (fig 3b)  
region. These lymph nodes are FDG positive on PET (fig 3 c,d). PET/CT (fig 3e,f) confirmed 
the correlation of these findings. On histopathology these nodes were metastatic lymph 
nodes.  
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Fig. 4. A 60-year-old man with a spinocellular carcinoma in the left upper lobe. CT 
demonstrates the tumor in the left upper lobe (fig 4a), even as an enlarged lymph node in 
the right hilum (fig 4c)  and not enlarged mediastinal lymph nodes (fig 4b) . PET and 
PET/CT (fig 4d-i) demonstrate FDG uptake on the tumor and the lymph nodes visible on 
CT. Histopathology examination of these lymph nodes could not demonstrate metastatic 
disease. These were false positive lymph nodes. 
5. Assessment of M stage 
The observation of distant metastases in patients with NSCLC has major implications for 
management and prognosis. In total, 40% of patients with NSCLC have distant metastases at 
presentation, most commonly in the adrenal glands, bones, liver or brain [46, 47]. After 
radical treatment for seemingly localized disease, 20% of these patients develop an early 
distant relapse, probably due to systemic micro-metastases that were present at the time of 
initial staging [48].  
In general, a routine search for disease beyond the chest and the upper abdomen in 
asymptomatic patients is not undertaken with CT and so a staging CT for lung cancer is 
usually done caudally from the thoracic inlet to the inferior edge of the liver, including the 
adrenal glands. Many reports suggest that FDG-PET is more sensitive than CT in the 
diagnosis of extrathoracic metastases. Sensitivity rates of 88–100% have been reported in 
characterizing adrenal masses detected on CT in patients with lung and other primary 
cancers [49, 50]. Similarly, in a small series, figures of 100% sensitivity and specificity have 
been recorded in the detection of liver metastases from NSCLC with PET [51]. PET is also  
 
www.intechopen.com
 
Computed Tomography – Clinical Applications 
 
262 
 
Fig. 5. A 88-year-old man with a spinocellular carcinoma of the right lower lobe. CT 
demonstrates a central tumor in the right lower lobe (fig 5a) and an enlarged lymph node in 
the right paratracheal region (fig 5b). PET (fig 5c-d) showed FDG-uptake on the tumor, but 
could not demonstrate FDG uptake on the CT-enlarged lymph node. Histopathological 
examination showed a metastatic lymph node in the right paratracheal region.  
stated to be more specific than, and equally sensitive as, bone scintigraphy in the detection 
of bone metastases [52]. However, PET is less useful in recognizing brain metastases, owing 
to high levels of glucose uptake within normal brain tissue. The significance of isolated 
areas of avid FDG uptake, without anatomical reference, is uncertain and exclusion of 
malignancy by PET requires caution in the case of small lesions (<1 cm) [39].  
The advantage of integrated PET/CT imaging is the ability to exactly locate a focal 
abnormality on PET images.  PET/CT was found to be the best noninvasive imaging 
technique in evaluating distant metastases in several studies [20]. Cerfolio et al. [28] proved 
that PET/CT predicts the metastatic disease better than PET alone: 92% versus 87% correctly 
predicted. PET/CT and PET, respectively, correctly predicted 100% versus 86% of bone 
metastases, 80% versus 100% of the chest wall or pleural metastases, 100% versus 100% of the 
liver metastases, 66% versus 66% of the adrenal metastases and 100% versus 50% of the 
gastrointestinal metastases. PET/CT identified one brain metastasis while PET missed this 
metastasis.  
6. Restaging and tumor recurrence 
Patients with stage IIIA lung cancer and in whom neoadjuvant treatment results in 
“downstaging” may be candidates for potentially curative surgery. While PET is very good 
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in the initial nodal staging of lung cancer, PET alone has limited accuracy for mediastinal 
restaging after chemotherapy [53]. Furthermore, the results of remediastinoscopy are 
disappointing. De Leyn et al. used surgical findings as the gold standard for comparing the 
accuracy of PET/CT for N-staging with that of remediastinoscopy after neoadjuvant 
therapy. In this setting, PET/CT was more accurate than remediastinoscopy (83% versus 
60%; p<0.05) and significantly more accurate than PET or CT alone [54].  
Progression of disease may occur as intrathoracic recurrence or metastases. The 
differentiation of recurrent lung cancer and post-therapeutic changes remains a problem for 
radiological imaging. Both processes can appear identical on CT images, which present a 
challenge to the use of this modality in the post-treatment patient with lung cancer. 
Conversely scar and fibrosis are, by definition, dead tissue and should not result in any FDG 
uptake, which makes PET or PET/CT ideal for this indication. A high accuracy of F-18 FDG-
PET or PET/CT in distinguishing recurrent disease from benign treatment effects has been 
reported [55-57]. PET has been shown to have a sensitivity of 98%-100% for the 
differentiation of tumor from post-treatment changes in the lung [26].  
Concerning restaging following extensive surgery or radiation, it is common to have some 
degree of scarring within the remaining lung parenchyma. Serial CT is typically used to 
follow these patients up. With PET and PET/CT, most of these patients can be evaluated 
more accurately and earlier than with other imaging modalities. Much of the FDG uptake 
due to inflammation from surgery resolves relatively quickly. Therapy changes after 
radiation therapy resolves typically within 6 weeks, and these patients can be reevaluated at 
this time for residual or recurrent tumor. Patients should be evaluated a minimum of 2 
months after completion of therapy. Otherwise, post-therapeutic healing processes or 
radiation pneumonitis may result in false positive findings [23]. 
7. Radiation treatment and PET/CT 
In recent years, many of the radiation therapy planning systems have been upgraded to be 
able to incorporate both CT and PET data sets. Many also have the ability to fuse the two 
data sets by using the planning software. Some preliminary studies have shown that 
radiation portals and tumor volumes change up to 50% of the time when both PET and CT 
data sets are considered compared with the traditional CT planning method [58]. This 
anatomic and functional plan has the biggest effect when there are portions of a tumor that 
may not be visible or are not included on CT images alone. With both the anatomic and 
metabolic data, radiation oncologists are able to define viable tumor volume more 
accurately, as well as minimize the amount of exposure to normal tissue.[26] 
8. Conclusion 
Integrated PET/CT is the best imaging technique for T-staging; it is better than CT alone, 
PET alone and visual correlation of PET and CT. With integrated PET/CT, tumors can be 
better delineated from surrounding structures, such as chest wall, mediastinum or 
surrounding atelectasis, which is important in the exclusion of T3 or T4 stage. For N-
(re)staging, integrated PET/CT increases the specificity and positive predictive value, owing 
to the combination of metabolic and anatomic information. For M-staging, the additional 
value of integrated PET/CT is related to the availability of a whole-body CT and the better 
localization of FDG-hotspots. The CT part of the integrated PET/CT is often able to detect 
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and diagnose metastatic disease, obviating specific diagnostic CT examinations while the 
additional FDG hotspots detected with PET are better characterized when the CT 
information is used. However, there are still many indeterminate lesions that need 
histopathological proof, and integrated PET/CT can be helpful in guiding these 
interventional procedures.  
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